Zhejiang Dayang Biotech Group Co (003017) — Net Asset Quality Index
Zhejiang Dayang Biotech Group Co (003017) has a Net Asset Quality Index of 62.4% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥1.88 Billion minus total liabilities of CN¥706.73 Million yields net assets of CN¥1.17 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Read Zhejiang Dayang Biotech Group Co balance sheet liabilities for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
Zhejiang Dayang Biotech Group Co Net Asset Quality Index Over Time (2013–2025)
This chart shows how Zhejiang Dayang Biotech Group Co's Net Asset Quality Index has evolved across 13 annual periods from 2013 to 2025. As of March 2026, the index stands at 62.4%, representing net assets of CN¥1.17 Billion against total assets of CN¥1.88 Billion CNY. For live market cap and overall valuation, see market value of Zhejiang Dayang Biotech Group Co.
Annual Net Asset Quality Index for Zhejiang Dayang Biotech Group Co (2013–2025)
The table below presents the year-by-year Net Asset Quality Index for Zhejiang Dayang Biotech Group Co from 2013 to 2025, covering 13 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check Zhejiang Dayang Biotech Group Co (003017) strategic investment index to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 62.5% | CN¥1.14 Billion | CN¥1.82 Billion | CN¥681.72 Million | ▼ -1.2 pp |
| 2024 | 63.7% | CN¥1.05 Billion | CN¥1.65 Billion | CN¥600.40 Million | ▼ -1.5 pp |
| 2023 | 65.2% | CN¥1.01 Billion | CN¥1.55 Billion | CN¥538.47 Million | ▼ -0.1 pp |
| 2022 | 65.3% | CN¥985.05 Million | CN¥1.51 Billion | CN¥522.92 Million | ▼ -6.8 pp |
| 2021 | 72.1% | CN¥990.71 Million | CN¥1.37 Billion | CN¥383.64 Million | ▼ -5.9 pp |
| 2020 | 78.0% | CN¥958.13 Million | CN¥1.23 Billion | CN¥270.67 Million | ▲ +0.8 pp |
| 2019 | 77.2% | CN¥498.09 Million | CN¥645.60 Million | CN¥147.51 Million | ▲ +3.9 pp |
| 2018 | 73.2% | CN¥440.62 Million | CN¥601.61 Million | CN¥160.99 Million | ▲ +7.4 pp |
| 2017 | 65.8% | CN¥337.71 Million | CN¥513.08 Million | CN¥175.37 Million | ▲ +16.7 pp |
| 2016 | 49.1% | CN¥229.35 Million | CN¥466.72 Million | CN¥237.37 Million | ▲ +3.4 pp |
| 2015 | 45.7% | CN¥209.76 Million | CN¥458.88 Million | CN¥249.12 Million | ▲ +3.2 pp |
| 2014 | 42.5% | CN¥196.87 Million | CN¥463.30 Million | CN¥266.43 Million | ▲ +0.0 pp |
| 2013 | 42.5% | CN¥187.42 Million | CN¥441.35 Million | CN¥253.93 Million | — |